These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 30861690)

  • 1. Effects of high-density lipoprotein targeting treatments on cardiovascular outcomes: A systematic review and meta-analysis.
    Riaz H; Khan SU; Rahman H; Shah NP; Kaluski E; Lincoff AM; Nissen SE
    Eur J Prev Cardiol; 2019 Mar; 26(5):533-543. PubMed ID: 30861690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients.
    Keene D; Price C; Shun-Shin MJ; Francis DP
    BMJ; 2014 Jul; 349():g4379. PubMed ID: 25038074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Extended-Release Niacin on Quartile Lp-PLA
    Lyubarova R; Albers JJ; Marcovina SM; Yao Y; McBride R; Topliceanu A; Anderson T; Fleg JL; Desvigne-Nickens P; Kashyap ML; McGovern ME; Boden WE
    J Cardiovasc Pharmacol Ther; 2019 Nov; 24(6):534-541. PubMed ID: 31131629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient considerations and clinical impact of cholesteryl ester transfer protein inhibitors in the management of dyslipidemia: focus on anacetrapib.
    Miyares MA; Davis K
    Vasc Health Risk Manag; 2012; 8():483-93. PubMed ID: 22977305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of Niacin in Current Clinical Practice: A Systematic Review.
    Garg A; Sharma A; Krishnamoorthy P; Garg J; Virmani D; Sharma T; Stefanini G; Kostis JB; Mukherjee D; Sikorskaya E
    Am J Med; 2017 Feb; 130(2):173-187. PubMed ID: 27793642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.
    Kones R
    Vasc Health Risk Manag; 2013; 9():617-70. PubMed ID: 24174878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of HDL-modifiers on cardiovascular outcomes: a meta-analysis of randomized trials.
    Verdoia M; Schaffer A; Suryapranata H; De Luca G
    Nutr Metab Cardiovasc Dis; 2015 Jan; 25(1):9-23. PubMed ID: 25439661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib.
    Yvan-Charvet L; Kling J; Pagler T; Li H; Hubbard B; Fisher T; Sparrow CP; Taggart AK; Tall AR
    Arterioscler Thromb Vasc Biol; 2010 Jul; 30(7):1430-8. PubMed ID: 20448206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Lipid-Lowering Therapy on Mortality According to the Baseline Non-HDL Cholesterol Level: A Meta-Analysis.
    Masson W; Lobo M; Siniawski D; Molinero G; Huerín M; Nogueira JP
    High Blood Press Cardiovasc Prev; 2019 Aug; 26(4):263-272. PubMed ID: 31313082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical benefit from pharmacological elevation of high-density lipoprotein cholesterol: meta-regression analysis.
    Hourcade-Potelleret F; Laporte S; Lehnert V; Delmar P; Benghozi R; Torriani U; Koch R; Mismetti P
    Heart; 2015 Jun; 101(11):847-53. PubMed ID: 25872524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Niacin-ER/statin combination for the treatment of dyslipidemia: focus on low high-density lipoprotein cholesterol.
    Chrysant SG; Ibrahim M
    J Clin Hypertens (Greenwich); 2006 Jul; 8(7):493-9; quiz 500-1. PubMed ID: 16849903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors.
    Chapman MJ; Le Goff W; Guerin M; Kontush A
    Eur Heart J; 2010 Jan; 31(2):149-64. PubMed ID: 19825813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between triglycerides and cardiovascular events in primary populations: a meta-regression analysis and synthesis of evidence.
    Stauffer ME; Weisenfluh L; Morrison A
    Vasc Health Risk Manag; 2013; 9():671-80. PubMed ID: 24204156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
    Reiner Z
    Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential effects of fenofibrate and extended-release niacin on high-density lipoprotein particle size distribution and cholesterol efflux capacity in dyslipidemic patients.
    Franceschini G; Favari E; Calabresi L; Simonelli S; Bondioli A; Adorni MP; Zimetti F; Gomaraschi M; Coutant K; Rossomanno S; Niesor EJ; Bernini F; Benghozi R
    J Clin Lipidol; 2013; 7(5):414-22. PubMed ID: 24079282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CETP-Inhibition and HDL-Cholesterol: A Story of CV Risk or CV Benefit, or Both.
    Nicholls SJ
    Clin Pharmacol Ther; 2018 Aug; 104(2):297-300. PubMed ID: 29901215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-statin interventions in the prevention of cardiovascular events: Sex-based meta-analysis.
    Das A; Roy B; Bandyopadhyay D; Dasgupta S; Chakraborty S; Soudant C; Gulati M; Ray KK; Lavie CJ
    Prog Cardiovasc Dis; 2020; 63(3):228-232. PubMed ID: 32224114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thinking beyond low-density lipoprotein cholesterol: strategies to further reduce cardiovascular risk.
    Sharma RK; Singh VN; Reddy HK
    Vasc Health Risk Manag; 2009; 5():793-9. PubMed ID: 19812691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis.
    D'Andrea E; Hey SP; Ramirez CL; Kesselheim AS
    JAMA Netw Open; 2019 Apr; 2(4):e192224. PubMed ID: 30977858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Journey through cholesteryl ester transfer protein inhibition: from bench to bedside.
    Karalis I; Rensen PC; Jukema JW
    Circ Cardiovasc Qual Outcomes; 2013 May; 6(3):360-6. PubMed ID: 23674310
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.